Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020108735 - ANTIBODIES TO CYTOMEGALOVIRUS INTERLEUKIN-10

Publication Number WO/2020/108735
Publication Date 04.06.2020
International Application No. PCT/EP2018/082603
International Filing Date 26.11.2018
IPC
C07K 16/24 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
A61P 31/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
CPC
A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
C07K 16/244
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
244Interleukins [IL]
C07K 2317/33
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
30characterized by aspects of specificity or valency
33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
C07K 2317/76
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
70characterized by effect upon binding to a cell or to an antigen
76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
C07K 2317/92
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
90characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applicants
  • BLINK BIOMEDICAL SAS [FR]/[FR]
Inventors
  • BELTRAMINELLI, Nicola
  • GARRONE, Pierre
  • MARTIN, Adrianne
  • MANDRON, Virginie
Agents
  • SPILLMANN, Adrian
Priority Data
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIBODIES TO CYTOMEGALOVIRUS INTERLEUKIN-10
(FR) ANTICORPS DIRIGÉS CONTRE L'INTERLEUKINE-10 DU CYTOMÉGALOVIRUS
Abstract
(EN)
Described herein are antibodies specific for human cytomegalovirus (hCMV) interleukin (IL)-10 (hcmvIL-10) which do not cross-react with human cellular IL-10 (hIL-10), Epstein-Barr Virus IL-10 (ebvIL-10) or Rhesus macaque CMV IL-10 (RhcmvIL-10). A subset of the disclosed antibodies cross- react with latency-associated hcmvIL-10 (LAcmvIL-10). The disclosed antibodies are capable of inhibiting biological activities of hcmvIL-10 and may be used for diagnostic or therapeutic purposes.
(FR)
L'invention concerne des anticorps spécifiques de l'interleukine (IL)-10 du cytomégalovirus (hCMV) humain (hcmvIL-10) qui n'ont pas de réactions croisées avec l'IL-10 cellulaire humaine (hIL-10), le virus d'Epstein-Barr IL-10 (ebvIL-10) ou le macaque rhésus CMV IL-10 (RhcmvIL-10). Un sous-ensemble des anticorps selon l'invention a une réaction croisée avec hcmvIL-10 associé à la latence (LAcmvIL-10). Les anticorps selon l'invention sont capables d'inhiber des activités biologiques de hcmvIL-10 et peuvent être utilisés à des fins diagnostiques ou thérapeutiques.
Latest bibliographic data on file with the International Bureau